2(1H)-喹啉酮,5-溴-3,4-二氢- | 103854-24-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2(1H)-喹啉酮,5-溴-3,4-二氢-
• 中文别名: DL-2,4-二甲基苯丙氨酸
• 英文名称: 2,4-dimethyl-phenylalanine
• 英文别名: 2,4-Dimethyl-phenylalanin；2-amino-3-(2,4-dimethylphenyl)propanoic acid；2-azaniumyl-3-(2,4-dimethylphenyl)propanoate
• CAS: 103854-24-6
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: ZEWXVRJSLTXWON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

文献信息

• SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS
  申请人：Wolf Christian

  公开号：US20070265255A1

  公开（公告）日：2007-11-15

  One aspect of the invention relates to chiral bisoxazolidines and their use in asymmetric catalysis. The chiral bisoxazolidines are a novel class of compounds that is expected to find multiple applications, for example, in asymmetric synthesis. For example, a bisoxazolidine ligand enabled the catalytic enantioselective alkynylation and alkylation of a range of aromatic and aliphatic aldehydes, generating chiral propargylic alcohols and secondary alcohols in high yields and enantiomeric excess.

  该发明的一个方面涉及手性双恶唑啉及其在不对称催化中的应用。这种手性双恶唑啉是一种新型化合物类，预计将在多个领域得到应用，例如在不对称合成中。例如，一种双恶唑啉配体使得对一系列芳香族和脂肪族醛的催化不对称炔基化和烷基化成为可能，产生高产率和对映选择性的手性丙炔醇和二级醇。
• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020065248A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及化合物的结构公式（I）：其中A1为亚甲基、乙烯基或丙烯基，A2为N或CR5，或其立体异构体形式、立体异构体混合物或药用盐形式，用作HCV NS3蛋白酶的抑制剂，以及包含相同化合物的药物组合物和诊断试剂盒，以及用于治疗病毒感染或作为测定标准或试剂的方法。
• [EN] FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO<br/>[FR] AGENTS THÉRAPEUTIQUES ACTIVÉS PAR FAP, ET UTILISATIONS ASSOCIÉES
  申请人：TUFTS COLLEGE

  公开号：WO2015192123A1

  公开（公告）日：2015-12-17

  Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP- expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

  本文披露了细胞毒性蒽环类似物（如阿霉素）和其他治疗剂的前药，这些前药通过成纤维细胞激活蛋白（FAP）选择性地被切割和激活。这些前药可用于将细胞毒性和其他药物靶向输送至表达FAP的组织，包括癌症（如实体肿瘤）。还提供了包含这些前药的药物化合物，以及使用这些前药治疗由FAP上调引起的疾病的方法，例如癌症、纤维化和炎症。
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION D'UNE POLYMÉRASE VIRALE
  申请人：BIOCRYST PHARM INC

  公开号：WO2013158746A1

  公开（公告）日：2013-10-24

  Provided are compounds of Formula (I) as described herein. Compounds of Formula (I) are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula (I), as well as methods of treating viral infections using compounds of Formula (I).

  本文描述的是Formula (I)的化合物。Formula (I)的化合物在抑制病毒RNA聚合酶活性和病毒复制的方法中很有用。还提供了包含Formula (I)化合物的药物组合物，以及使用Formula (I)化合物治疗病毒感染的方法。
• Peptide inhibitors of hepatitis C virus NS3 protein
  申请人：——

  公开号：US20020177725A1

  公开（公告）日：2002-11-28

  This invention relates to a novel class of peptides having the Formula (I): 1 Which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

  本发明涉及一类新型肽的公式(I)：1，其作为丝氨酸蛋白酶抑制剂具有用途，更具体地作为丙型肝炎病毒（HCV）NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗HCV感染的方法。